Company intelligence / Profile preview

AXCIAN

San Diego, California, United Statesnvsos.gov ↗

Ownership: Private
Development stage: Other

Overview

AXIM has developed and commercialized two FDA-cleared point-of-care diagnostic tests for Dry Eye Disease. The company’s tear-based testing platform has undergone successful clinical validation and is being adopted by eye care professionals. A rapid 10-minute cancer biomarker test is under development.

Therapeutic areas: OphthalmologyImmunologyOncology
Modalities: DeviceDiagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

Verséa Ophthalmic (commercialization partner for digital assay reader)

Beyond the preview

Go deeper on AXCIAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXCIAN.

Explore the full profile